IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial
1. IGC reported progress in Phase 2 trial for Alzheimer's treatments. 2. The company maintains a $12M credit facility for future initiatives.